

HOTLINE: Effective August 15, 2022

New Test	3004781 Fetal Aneuploidy Screening with Microdeletions	FAS MD
	History Form for Fetal Aneuploidy Screening REQUIRED Additional Technical Info	ormation
	Optional Informed Consent Form for Fetal Aneuploidy Screening	
Methodology: Performed: Reported:	Targeted Sequencing with SNPs Varies 12-14 days	
Specimen Required: Collect: Maternal whole blood in Cell-Free DNA BCT tube. A kit must be ordered prior to specimen collection (ARUP Supply #50223) available online through eSupply using ARUP Connect [™] or by contacting ARUP Client Services at (800) 522-2787. Specimen Preparation: Transport 20 mL maternal blood in Cell-Free DNA BCT tube. (Min: 16 mL) Storage/Transport Temperature: Room temperature. Remarks: Patient history form is required prior to testing. Stability (collection to initiation of testing): Ambient: 5 days; Refrigerated: Unacceptable; Frozen: Unacceptable		
Reference Interval: By report		
Interpretive D Refer to report.	ata:	
Note: Testing ut	ilizes a single-nucleotide polymorphism (SNP)/informatics-based approach to detect fetal copy number for the f	ve chromosomes

Note: Testing utilizes a single-nucleotide polymorphism (SNP)/informatics-based approach to detect fetal copy number for the five chromosomes responsible for most live-birth aneuploidies (chromosomes 13, 18, 21, X, Y, and triploidy) and certain specific microdeletion syndromes (see current list of microdeletion syndromes listed under "Ordering Recommendations"). This is a screening test to help identify fetuses at risk for Down syndrome, trisomy 18, trisomy 13, and Turner syndrome, as well as fetuses affected with the specified microdeletion syndromes listed. Test should not be considered diagnostic. All positive results should be confirmed by amniocentesis or CVS.

CPT Code(s): 81420; 81422

New York DOH Approved.

HOTLINE NOTE: Refer to the Test Mix Addendum for interface build information.